Recent 8-K filings for GRI
Highest-materiality recent filing
GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF
- Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.
- Biomarkers improved: type VI collagen remodeling shifted from fibrogenic (+10%) to fibrolytic (-7%), suggesting fibrosis resolution.
-
GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF
Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.
-
GRI Bio expands ATM equity offering capacity from $10M to $60M via H.C. Wainwright amendment
Amendment to At The Market Offering Agreement increases aggregate offering price to $60 million.
-
GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF
Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.
-
GRI Bio conditionally regains Nasdaq equity compliance after prior deficiency
Nasdaq Staff notified GRI Bio on Jan 15, 2026 that it conditionally regained compliance with the Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).
-
Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.
-
GRI Bio reports positive Phase 2a immune data for GRI-0621 in IPF
Phase 2a data shows GRI-0621 reduces pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β) and increases anti-fibrotic IFN-γ in BAL and PBMC after 12 weeks.
-
GRI Bio launches $6.7M public offering of common stock and warrants
Offering comprises 2.6M shares, 8.1M pre-funded warrants ($0.0001/share), and 10.7M Series F warrants ($0.75/share) at $0.75 per unit.
-
GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF
Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.
-
GRI Bio reports positive Phase 2a data for GRI-0621 in IPF; primary endpoint met
Phase 2a trial (35 IPF subjects, 2:1 randomization) met primary safety endpoint; GRI-0621 well tolerated over 12 weeks with no treatment-related SAEs.
-
GRI BIO receives Nasdaq delisting notice for stockholders' equity deficiency
Nasdaq notified GRI BIO of non-compliance with minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).
-
6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.
-
IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.
-
GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025
Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.
-
GRI Bio dismisses auditor Sadler Gibb, appoints WithumSmith+Brown as new independent accountant.
Audit Committee dismissed Sadler Gibb on April 11, 2025; no disagreements on accounting principles or practices.
-
GRI Bio prices $5M public offering of shares and warrants; net proceeds ~$4.2M
Priced public offering of 1,388,888 units at $3.60 each (share or pre-funded warrant plus Series E-1, E-2, E-3 warrants).
-
GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025
Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.
-
GRI Bio regains compliance with Nasdaq minimum bid price rule
Received Nasdaq notice on March 10, 2025 confirming compliance with Listing Rule 5550(a)(2).
-
GRI Bio announces 1-for-17 reverse stock split effective Feb 21, 2025
Reverse split at 1:17 ratio, effective 4:01 p.m. ET on Feb 21, 2025; post-split trading begins Feb 24, 2025 on Nasdaq under symbol GRI.
-
GRI Bio raises $13.9M in gross proceeds since Jan 2024; cash runway into mid Q1 2025
Closed Oct 22 warrant exercise for 762,236 shares raising $0.8M gross proceeds.
-
Received Nasdaq letter on Sept 10, 2024 for failing minimum bid price of $1.00 over 30 consecutive business days.
-
GRI Bio receives Nasdaq deficiency notice for minimum bid price non-compliance
Received Nasdaq letter on Sept 10, 2024; closing bid price below $1.00 for 30 consecutive business days.
-
GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track
Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).
-
GRI Bio regains compliance with Nasdaq continued listing standards
Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).
-
GRI Bio prices $4.0M public offering of shares and warrants at $1.83/unit
Offering of 2,185,793 shares (or equivalents) plus Series C-1 and C-2 warrants at $1.83 per unit.
-
GRI Bio CMO Albert Agro reduced to 70 hrs/month, salary cut to $100k
CMO Albert Agro's base salary reduced from $325,000 to $100,000 annually.
-
GRI Bio announces 1-for-13 reverse stock split to regain Nasdaq compliance
Reverse split at 1-for-13 effective 4:01 p.m. ET June 17, 2024; split-adjusted trading starts June 18, 2024.
-
GRI Bio receives Nasdaq delisting determination; plans to appeal by May 28, 2024
Received Nasdaq Staff determination letter on May 21, 2024, for non-compliance with stockholders' equity rule (Rule 5550(b)) after initial 180-day cure period ended May 20, 2024.
-
GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024
Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.
-
GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering
Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material